CASE REPORT
Percutaneous device closure of atrial septal defect in HIV-positive patient: a challenge for interventionist
 
More details
Hide details
1
Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India
 
 
Submission date: 2020-02-11
 
 
Acceptance date: 2020-05-17
 
 
Publication date: 2020-12-12
 
 
HIV & AIDS Review 2020;19(4):289-291
 
KEYWORDS
TOPICS
ABSTRACT
Atrial septal defect (ASD) is one of the most common congenital heart defects. Intracardiac repair via midline sternotomy or right thoracotomy and cardiopulmonary bypass have been considered the standard treatment for the closure of atrial septal defects, but transcatheter closure with Amplatzer septal occluder has recently become an alternative option. Transcatheter device closure of secundum ASD is a more than a decade old technology. This has become an alternative to surgical therapy, and has been regarded as generally safe and effective device closure. Device embolization is a potential complication of every attempted ASD closure, and the causative factors include undersized device, floppy rim, and operator-related technical issues, such as malposition during a “push-pull” maneuver. In this paper, we report a 32-year-old HIV positive female patient who presented with gradual onsite of dyspnea, NYHA class II, and successfully underwent a device closure of large atrial septal defect.
 
REFERENCES (9)
1.
Chu MW, Losenno KL, Fox SA, et al. Clinical outcomes of minimally invasive endoscopic and conventional sternotomy approaches for atrial septal defect repair. Can J Surg 2014; 57: E75-81.
 
2.
Petit CJ, Justino H, Pignatelli RH, et al. Percutaneous atrial septal defect closure in infants and toddlers: predictors of success. Pediatr Cardiol 2013; 34: 220-225.
 
3.
Campbell M. Natural history of atrial septal defect. Br Heart J 1970; 32: 820-826.
 
4.
Craig RJ, Selzer A. Natural history and prognosis of atrial septal defect. Circulation 1968; 37: 805-815.
 
5.
Moore J, Hegde S, El-Said H, et al. Transcatheter device closure of atrial septal defects: a safety review. JACC Cardiovasc Interv 2013; 6: 433-442.
 
6.
Podnar T, Martanovic P, Gavora P, et al. Morphological variations of secundum-type atrial septal defects: feasibility for percutaneous closure using Amplatzer septal occluders. Catheter Cardiovasc Interv 2001; 53: 386-391.
 
7.
Lai WW, Lipshultz SE, Easley KA, et al. Prevalence of congenital cardiovascular malformations in children of human immunodeficiency virus-infected women: the prospective P2C2 HIV multicenter study. P2C2 HIV Study Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland. J Am Coll Cardiol 1998; 32: 1749-1755.
 
8.
Diógenes MSB, Succi R, Machado DM, et al. Cardiac longitudinal study of children perinatally exposed to human immunodeficiency type 1. Arq Bras Cardiol 2005; 85: 233-240.
 
9.
Barbaro G, Fisher SD, Lipshultz SE. Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect Dis 2001; 1: 115-124.
 
eISSN:1732-2707
ISSN:1730-1270
Journals System - logo
Scroll to top